Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Titel:
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
Auteur:
Molina, Jean-Michel Ward, Douglas Brar, Indira Mills, Anthony Stellbrink, Hans-Jürgen López-Cortés, Luis Ruane, Peter Podzamczer, Daniel Brinson, Cynthia Custodio, Joseph Liu, Hui Andreatta, Kristen Martin, Hal Cheng, Andrew Quirk, Erin